Amplio Spine signed a Letter of Intent to acquire the KeyLift Expandable Interlaminar Stabilization System family — comprising KeyLiftXS and KeyLiftXL, four sizes each — and related assets from FloSpine. Financial terms were not disclosed.
KeyLift received FDA 510(k) clearance in late 2023, with the first surgical implantation in May 2024. Upon closing, Amplio Spine will fully commercialize the platform nationally as the only U.S. company offering an expandable, patent-protected interlaminar stabilization device with both XS and XL sizing. The asset purchase is expected to close in 2Q26.
Amplio Spine is entirely founder-funded; no outside capital has been raised in connection with this transaction.
Amplio Spine signed a Letter of Intent to acquire the KeyLift Expandable Interlaminar Stabilization System family — comprising KeyLiftXS and KeyLiftXL, four sizes each — and related assets from FloSpine. Financial terms were not disclosed.
Amplio Spine signed a Letter of Intent to acquire the KeyLift Expandable Interlaminar Stabilization System family — comprising KeyLiftXS and KeyLiftXL, four sizes each — and related assets from FloSpine. Financial terms were not disclosed.
KeyLift received FDA 510(k) clearance in late 2023, with the first surgical implantation in May 2024. Upon closing, Amplio Spine will fully commercialize the platform nationally as the only U.S. company offering an expandable, patent-protected interlaminar stabilization device with both XS and XL sizing. The asset purchase is expected to close in 2Q26.
Amplio Spine is entirely founder-funded; no outside capital has been raised in connection with this transaction.
Copy to clipboard 
